Skip Navigation


Carcinogenesis Advance Access originally published online on December 4, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/4/559    most recent
bgh039v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by McGrath, M.
Right arrow Articles by De Vivo, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGrath, M.
Right arrow Articles by De Vivo, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 25, No. 4, 559-565, April 2004
Carcinogenesis vol.25 no.4 © Oxford University Press 2004; all rights reserved.

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility

Monica McGrath1,5, Susan E. Hankinson1,4, Lori Arbeitman4, Graham A. Colditz1,4, David J. Hunter1,–4 and Immaculata De Vivo1,3,4

1 Department of Epidemiology and 2 Department of Nutrition, 3 Program in Molecular Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA and 4 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Estrogen production and metabolism play critical roles in the development and pathogenesis of endometrial carcinoma. Cytochrome P450 1B1 (CYP1B1) and catechol-O-methyltransferase (COMT) are two key enzymes in the estrogen metabolism pathway that result in the hydroxylation and conjugation of estradiol, respectively. We evaluated the association between the CYP1B1 Leu432Val and CYP1B1 Asn453Ser polymorphisms and the COMT Val158Met polymorphism and invasive endometrial cancer risk in a case-control study nested within the Nurses' Health Study (n = 222 cases, 666 controls). We also evaluated whether body mass index (BMI), postmenopausal hormone (PMH) use and cigarette smoking modified the associations of the CYP1B1 and COMT genotypes and endometrial cancer risk. Conditional logistic regression was used to calculate the adjusted odds ratios (OR) and 95% confidence intervals (CI) to quantify the risk of endometrial cancer among subjects who had at least one variant allele compared with subjects who were homozygous for the wild-type allele. Carriers of the CYP1B1 Ser allele had a statistically significant decreased risk of endometrial cancer (OR = 0.62; 95% CI, 0.42–0.91); there was no significant association between the CYP1B1 Val allele and endometrial cancer risk (OR = 1.10; 95% CI, 0.75–1.59). Compared with the COMT Val/Val wildtype genotype, the adjusted OR of endometrial cancer for women with the COMT Val/Met or COMT Met/Met genotype was 0.96 (95% CI, 0.65–1.43). We did not observe any effect modification by BMI, PMH use and cigarette smoking for the CYP1B1 and COMT genotypes. Our data suggest, that the CYP1B1 Ser allele may decrease endometrial cancer risk by altering the production of catechol estrogens. However, further studies are warranted to elucidate the role of CYP1B1 in endometrial cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
F. Chitsazian, B. K. Tusi, E. Elahi, H. A. Saroei, M. H. Sanati, S. Yazdani, M. Pakravan, N. Nilforooshan, Y. Eslami, M. A. Z. Mehrjerdi, et al.
CYP1B1 Mutation Profile of Iranian Primary Congenital Glaucoma Patients and Associated Haplotypes
J. Mol. Diagn., July 1, 2007; 9(3): 382 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck, A. B. Troxel, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, R. Schinnar, J. A. Berlin, and B. L. Strom
Lack of Effect Modification between Estrogen Metabolism Genotypes and Combined Hormone Replacement Therapy in Postmenopausal Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1318 - 1320.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck, A. B. Troxel, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, et al.
Pairwise Combinations of Estrogen Metabolism Genotypes in Postmenopausal Breast Cancer Etiology
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 444 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. H. Tao, Q. Cai, W. H. Xu, N. Kataoka, W. Wen, W. Zheng, Y. B. Xiang, Z.-F. Zhang, and X. O. Shu
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Endometrial Cancer Risk in Chinese Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2570 - 2573.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al.
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.
J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Tanaka, M. Sasaki, H. Shiina, T. Tokizane, M. Deguchi, H. Hirata, Y. Hinoda, N. Okayama, Y. Suehiro, S. Urakami, et al.
Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 238 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Aklillu, S. Ovrebo, I. V. Botnen, C. Otter, and M. Ingelman-Sundberg
Characterization of Common CYP1B1 Variants with Different Capacity for Benzo[a]pyrene-7,8-Dihydrodiol Epoxide Formation from Benzo[a]pyrene
Cancer Res., June 15, 2005; 65(12): 5105 - 5111.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Doherty, N. S. Weiss, R. J. Freeman, D. A. Dightman, P. J. Thornton, J. R. Houck, L. F. Voigt, M. A. Rossing, S. M. Schwartz, and C. Chen
Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 357 - 366.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Bandiera, S. Weidlich, V. Harth, P. Broede, Y. Ko, and T. Friedberg
Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 Expression
Mol. Pharmacol., February 1, 2005; 67(2): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z.-H. Chen, Y.-J. Hurh, H.-K. Na, J.-H. Kim, Y.-J. Chun, D.-H. Kim, K.-S. Kang, M.-H. Cho, and Y.-J. Surh
Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells
Carcinogenesis, October 1, 2004; 25(10): 2005 - 2013.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.